12/18/2007

The FDA has given expanded approval to Genzyme Corp.'s thyroid cancer drug Thyrogen, the Cambridge, Mass.-based company announced Monday. The new approval allows the use of Thyrogen in combination with radioiodine to destroy any remaining thyroid tissue in patients who have had their cancerous thyroids removed.

Related Summaries